FHD: An index to evaluate drug elimination by hemodialysis

American Journal of Nephrology

Volumn 25, Issue 4, 2005, Pages 342-351

  Launay Vacher, Vincent ^a   Izzedine, Hassane ^a   Baumelou, Alain ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Drug removal; Hemodialysis

Indexed keywords

ABACAVIR; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; EVALUATION; F HD; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; SIMULATION; TIME; BIOLOGICAL MODEL; CHRONIC KIDNEY FAILURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL DIALYSIS;

EID: 23844438251     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086591     Document Type: Article

References (44)

1. Reidenberg MM, Drayer DE: Drug therapy in renal failure. Annu Rev Pharmacol Toxicol 1980;20:45-54.
2. Keller F, Wilms H, Schultze G, et al: Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 1983;19:201-205.
3. Golper TA, Wedel SK, Kaplan AA, et al: Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985;8:307-312.
4. Kober A, Sjoholm I, Borga O, Odar-Cederlof I: Protein binding of diazepam and digitoxin in uremic and normal serum. Biochem Pharmacol 1979;28:1037-1042.
5. Golper TA, Pulliam J, Bennett WM: Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med 1985;145:1651-1652.
6. Golper TA, Bennett WM: Drug removal by continuous arteriovenous haemofiltration: a review of the evidence in poisoned patients. Med Toxicol Adverse Drug Exp 1988;3:341-349.
7. Ronco C, Fabris A, Chiaramonte S, et al: Comparison of four different short dialysis techniques. Int J Artif Organs 1988;11:169-174.
8. Ronco C, Fabris A, Feriani M, et al: Technical and clinical evaluation of a new system for ultrafiltration control during hemodialysis. ASAIO Trans 1988;34:613-616.
9. Fabris A, La Greca G, Chiaramonte S, et al: Total solute extraction versus clearance in the evaluation of standard and short hemodialysis. ASAIO Trans 1988;34:627-629.
10. Ronco C, Fabris A, Feriani M, et al: Technical and clinical evaluation of a new synthetic low flux polysulphon membrane for hemodialysis. Int J Artif Organs 1989;12:450-460.
11. 2 modified cuprammonium rayon membrane: technical and clinical evaluation. Nephrol Dial Transplant 1988;3:440-447.
12. Klein E, Autian J, Bower JD, et al: Clinical evaluation: evaluation of hemodialyzers and dialysis membranes. Report of a study group for the Artificial Kidney-Chronic Uremia Program NIAMMDD-1977. Artif Organs 1979;3:47-61.
13. Gupta BB, Ding LH, Jaffrin MY, Baurmeister U: Comparison of polyamide and polypropylene membranes for plasma separation. Int J Artif Organs 1991;14:56-60.
14. De Bock V, Verbeelen D, Maes V, Sennesael J: Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989;4:635-639.
15. Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989;35:1409-1412.
16. Klein E, Holland FF, Eberle K: Comparison of solute permeability and rejection characteristics of normal and flux cellulose haemodialysis membranes. Proc Eur Dial Transplant Assoc 1979;16:198-204.
17. Asaba H, Bergstrom J, Furst P, et al: Removal of endogenous middle molecules by hemoperfusion. Artif Organs 1979;3:132-136.
18. Lau AH, Kronfol NO, John E: Increased vancomycin elimination with continuous hemofiltration. ASAIO Trans 1987;33:772-774.
19. Sprenger KG, Stephan H, Kratz W, et al: Optimising of hemodiafiltration with modern membranes? Contrib Nephrol 1985;46:43-60.
20. Reetze-Bonorden P, Böhler J, Keller E: Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993;24:362-379.
21. Izzedine H, Launay-Vacher V, Baumelou A, Deray G: An appraisal of anti-retroviral drugs in hemodialysis. Kidney Int 2001;60:821-830.
22. Gwilt PR, Perrier D: Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther 1978;24:154-161.
23. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications, ed 3. Baltimore, Williams & Wilkins, 1995, pp 443-462.
24. Izzedine H, Launay-Vacher V, Aymard G, et al: Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron 2001;89:62-67.
25. Izzedine H, Launay-Vacher V, Aymard G, et al: Pharmacokinetics of nevirapine in haemodialysis. Nephrol Dial Transplant 2001;16:192-193.
26. Block ER, Bennett JE, Livoti LG, et al: Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Ann Intern Med 1974;80:613-617.
27. Morgan DJ, Ching MS, Raymond K, et al: Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther 1983;34:248-253.
28. Daneshmend TK, Warnock DW: Clinical Pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983;8:17-42.
29. Lee CS, Wang LH, Marbury TC, et al: Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis. Clin Toxicol 1980;17:429-438.
30. Singlas E, Taburet AM, Borsa Lebas F, et al: Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis. Antimicrob Agents Chemother 1992;36:1519-1524.
31. Izzedine H, Aymard G, Launay-Vacher V, et al: Pharmacokinetics of Efavirenz in a patient on maintenance hemodialysis. AIDS 2000;14:618-619.
32. Oono S, Tabei K, Tetsuka T, Asano Y: The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol 1992;42:667-669.
33. Toon S, Ross CE, Gokal R, Rowland M: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990;29:221-226.
34. Izzedine H, Aymard G, Hamani A, et al: Indinavir pharmacokinetics in haemodialysis. Nephrol Dial Transplant 2000;15:1102-1103.
35. Johnson MA, Verpooten GA, Daniel MJ, et al: Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol 1998;46:21-27.
36. Izzedine H, Launay-Vacher V, Legrand M, et al: ABT 378/r a novel inhibitor of HIV-1 protease and hemodialysis. AIDS 2001;15:662-664.
37. Bassilios N, Launay-Vacher V, Hamani A, et al: Pharmacokinetics and dosage adjustment of rifabutine in one hemodialysis patient. Nephrol Dial Transplant 2002;17:531-532.
38. Izzedine H, Launay-Vacher V, Legrand M, et al: Pharmacokinetics of Ritonavir and Saquinavir in a haemodialysis patient. Nephron 2001;87:186-187.
39. Izzedine H, Launay-Vacher V, Jullien V, et al: Pharmacokinetics of Tenofovir in hemodialysis. Nephrol Dial Transplant 2003;18:1931-1933.
40. Izzedine H, Launay-Vacher V, Abbara C, et al: Pharmacokinetics of tramadol in a haemodialysis patient. Nephron 2002;92:755-756.
41. Launay-Vacher V, Izzedine H, Mercadal L, Deray G: Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6:313-316.
42. Singlas E, Pioger JC, Taburet AM, et al: Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989;46:190-197.
43. Bohler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999;72:S24-S28.
44. Cousin L, Le Berre M, Launay-Vacher V, Izzedine H, Deray G: Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant 2003;18:2227-2231.